argenx (NASDAQ:ARGX) Rating Reiterated by Wedbush

argenx (NASDAQ:ARGX)‘s stock had its “outperform” rating reissued by equities research analysts at Wedbush in a report issued on Thursday, Benzinga reports. They currently have a $521.00 price target on the stock. Wedbush’s price target would indicate a potential upside of 44.63% from the company’s current price.

ARGX has been the topic of several other research reports. Wells Fargo & Company upped their price target on argenx from $472.00 to $478.00 and gave the company an “overweight” rating in a research note on Tuesday, February 20th. Truist Financial upped their price target on argenx from $370.00 to $440.00 and gave the company a “buy” rating in a research note on Tuesday, March 5th. Wolfe Research started coverage on argenx in a research note on Thursday, February 15th. They issued a “peer perform” rating on the stock. Raymond James decreased their price target on argenx from $580.00 to $520.00 and set a “strong-buy” rating on the stock in a research note on Thursday, December 21st. Finally, William Blair lowered argenx from an “outperform” rating to a “market perform” rating in a research note on Wednesday, December 20th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $528.16.

argenx Stock Performance

NASDAQ ARGX opened at $360.23 on Thursday. The stock’s fifty day moving average is $387.43 and its two-hundred day moving average is $420.93. The firm has a market capitalization of $21.36 billion, a P/E ratio of -70.08 and a beta of 0.65. argenx has a fifty-two week low of $327.73 and a fifty-two week high of $550.76.

argenx (NASDAQ:ARGX) last released its quarterly earnings data on Thursday, February 29th. The company reported ($1.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.45). argenx had a negative return on equity of 16.97% and a negative net margin of 23.26%. The company had revenue of $417.84 million for the quarter, compared to analyst estimates of $378.60 million. During the same period last year, the firm posted ($0.70) EPS. As a group, sell-side analysts forecast that argenx will post -2.11 EPS for the current year.

Institutional Investors Weigh In On argenx

Several large investors have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD increased its holdings in argenx by 0.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,673,855 shares of the company’s stock worth $1,397,645,000 after purchasing an additional 14,340 shares during the period. Artisan Partners Limited Partnership increased its holdings in shares of argenx by 12.2% in the 4th quarter. Artisan Partners Limited Partnership now owns 3,174,477 shares of the company’s stock valued at $1,207,666,000 after acquiring an additional 346,178 shares during the last quarter. Capital World Investors increased its holdings in shares of argenx by 37.0% in the 4th quarter. Capital World Investors now owns 1,961,202 shares of the company’s stock valued at $746,099,000 after acquiring an additional 530,181 shares during the last quarter. Jennison Associates LLC increased its holdings in shares of argenx by 32.2% in the 3rd quarter. Jennison Associates LLC now owns 1,511,745 shares of the company’s stock valued at $743,219,000 after acquiring an additional 368,367 shares during the last quarter. Finally, Avoro Capital Advisors LLC increased its holdings in shares of argenx by 23.5% in the 4th quarter. Avoro Capital Advisors LLC now owns 1,234,567 shares of the company’s stock valued at $469,666,000 after acquiring an additional 234,567 shares during the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.